The Psychosis drugs in development market research report provides comprehensive information on the therapeutics under development for Psychosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Psychosis. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Psychosis - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Psychosis and features dormant and discontinued products.

GlobalData tracks 38 drugs in development for Psychosis by 30 companies/universities/institutes. The top development phase for Psychosis is preclinical with 18 drugs in that stage. The Psychosis pipeline has 37 drugs in development by companies and one by universities/ institutes. Some of the companies in the Psychosis pipeline products market are: Gabather, Acadia Pharmaceuticals and Cerevel Therapeutics.

The key targets in the Psychosis pipeline products market include 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A), D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2), and Muscarinic Acetylcholine Receptor M4 (CHRM4).

The key mechanisms of action in the Psychosis pipeline product include 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) Antagonist with eight drugs in Filing rejected/Withdrawn. The Psychosis pipeline products include five routes of administration with the top ROA being Oral and two key molecule types in the Psychosis pipeline products market including Small Molecule, and Monoclonal Antibody.

Psychosis overview

Psychosis is a condition that affects the mind and causes a loss of contact with reality. People with psychosis may experience hallucinations (seeing or hearing things that are not there) and delusions (believing things that are not true). Psychosis can be a symptom of various mental disorders, such as schizophrenia, bipolar disorder, or severe depression. It can also be triggered by stress, trauma, or substance use. Psychosis can affect a person’s thoughts, feelings, and behavior, and interfere with their daily functioning. Treatment for psychosis usually involves antipsychotic medication and psychotherapy. Early intervention can improve the outcome and recovery of people with psychosis.

For a complete picture of Psychosis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.